SCHEMBL20489592

SCHEMBL20489592

CCOC(=O)c1cnc2nc(SC)sc2c1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 6/20 0.41
MAPT P10636 6/20 0.41
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
POLB P06746 1/20 0.41
SYK P43405 1/20 0.39
CSNK1D P48730 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20489668 0.86 LMNA (0.47) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL20489613 0.85 LMNA (0.46) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL20489542 0.81 LMNA (0.43) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL14858881 0.72 LMNA (0.48) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL20489406 0.72 GABRP (0.36) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL18059277 0.72 LMNA (0.47) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL13255583 0.71 KMT2A (0.50) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL20489473 0.71 LMNA (0.31) LMNA
SCHEMBL17385467 0.69 LMNA (0.68) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL841384 0.69 LMNA (0.56) LMNAMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3372601-B1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2022-09-21 EP disclosed
US-10793582-B2 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-10-06 US disclosed
US-10793582-B2 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-10-06 US disclosed
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-08-01 US disclosed
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-08-01 US disclosed
EP-3372601-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2018-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND KAT2A, KAT7, KAT5 LMNA 4276/4885MEN1 4575/4885KMT2A 91/4885
US-10793582-B2 Bicyclic heterocyclic compound KAT2A, KAT7, KAT5 LMNA 4153/4885MEN1 4642/4885KMT2A 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.